Navigation Links
Project Zero Delay Accelerates Drug's Path to Clinical Trial
Date:8/3/2009

HOUSTON and WILMINGTON, Del., Aug. 3 /PRNewswire-FirstCall/ -- A phase I clinical trial enrolled its first patient only two days after U.S. Food and Drug Administration clearance of the experimental drug for a first-in-human cancer trial, a milestone that normally takes three to six months. Investigators from The University of Texas M. D. Anderson Cancer Center and pharmaceutical company AstraZeneca have reported their work in the Journal of Clinical Oncology published online on August 3(rd).

The joint effort, dubbed Project Zero Delay, is part of a strategic collaboration between the two organizations designed to safely accelerate development of new cancer drugs. In many cases that process takes about 12 years and the cost of bringing a new drug to patients has been estimated at around $1.3 billion. [Ref: J. A. DiMasi and H. G. Grabowski, "The Cost of Biopharmaceutical R&D: Is Biotech Different?" Managerial and Decision Economics 28 (2007): 469-479.]

"Project Zero Delay demonstrates how we can shrink the time it takes to bring new drugs to cancer patients," said Robert C. Bast Jr., M.D., vice president for translational research at M. D. Anderson and the paper's senior author. "We need to find out as promptly as possible whether new therapies will help. Zero Delay is a significant step in that direction. Close cooperation allowed us to eliminate unnecessary delays while fully meeting regulatory requirements for scientific and human safety review."

The key to Zero Delay was performing most tasks in parallel instead of sequentially, said lead author Razelle Kurzrock, M.D., professor and chair of M. D. Anderson's Department of Investigational Therapeutics. In addition, tasks usually done after FDA clearance of an Investigational New Drug (IND) application were instead done in advance. No administrati
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
2. Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in Miami
3. The Well Project Web Portal Receives Stevie(R) Website of the Year, InfoWorld 100 Award
4. Hospital Launches Landmark Emergency Medicine Project
5. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
6. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
7. ACORNs Oncology-focused Contract Research Organization Exceeds Projections
8. Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease
9. QMed, Inc. Receives 2-Year Extension of Medicare Coordinated Care Demonstration Project by CMS
10. TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project
11. Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... FRANCISCO, Calif. , Aug. 28, 2015  CytomX ... the treatment of cancer, today announced the filing of ... Securities and Exchange Commission (SEC) relating to a proposed ... of shares to be offered and the price range ... intends to list its common stock under the symbol ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ) ... on China,s Tobramycin Market, 2010-2019" report to their ... eye drop and ointment are the most common prescription ... caused by eye infection. Currently, dozens of enterprises in ... tobramycin, among which the Top 5 are s.a. Alcon- ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by Pharmacia ... prostaglandin receptor agonist which effectively reduces intraocular pressure. ... FDA, latanoprost (under the trade name of Xalatan) ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2
... 5, 2011 eCareSoft announced today the completion of ... their network of six hospitals with eCareSoft,s inpatient complete ... will incorporate eCareSoft,s proprietary fast-track implementation program enabling their ... order to qualify for 2011-2012 stimulus funds. ...
... EXTON, Pa., April 4, 2011 Morphotek®, Inc., ... it has acquired certain assets relating to a ... for an undisclosed upfront payment and future development ... of Prussia, PA, developed the tumor-targeting peptide (TTP) ...
Cached Medicine Technology:Central Texas Hospital Selects eCareSoft EHR Technology 2Morphotek®, Inc. Announces Acquisition of Tumor Targeting Assets From Transmolecular, Inc. 2Morphotek®, Inc. Announces Acquisition of Tumor Targeting Assets From Transmolecular, Inc. 3
(Date:8/31/2015)... , ... August 31, 2015 , ... In preparation for ... Research, maker of the BEAN™ personal sound amplifier, is offering caregivers “7 Reasons to ... as a way of coping with a variety of home healthcare challenges, specifically as ...
(Date:8/31/2015)... ... 31, 2015 , ... Move over shave cream. Roll over beard oil. There's ... to meet it. , Reports published this year (Mintel data) announced that barbershops are ... also reflects that men are getting more done at barbershops than a shave and ...
(Date:8/31/2015)... ... ... A year ago this month, Seniors Guide first hit stands in the ... the successful first year. , “We started the magazine with the goal of ... lives,” says Melissa Wolfert, founding Publisher for Seniors Guide Columbus. “Making the decision to ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... to announce a collaboration with Bright Pink® to raise money and awareness for ... donate $0.25 for each Hot Pink Sassy incandescent Mood-lite sold to Bright Pink® ...
(Date:8/31/2015)... , ... August 31, 2015 , ... It’s a lot ... executive director of GreenFields of Geneva. During his first days on the job, he’s ... been nice seeing them, and I like knowing that they’re living in such a ...
Breaking Medicine News(10 mins):Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 2Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 3Health News:MENAJI Anti-Aging Eraser a New Sure-Fire Add-On Product for Barbershops 2Health News:MENAJI Anti-Aging Eraser a New Sure-Fire Add-On Product for Barbershops 3Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 2Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3Health News:Friendship Senior Options Welcomes New Executive Director for GreenFields of Geneva 2
... CHICAGOANS , , CHICAGO, Dec. ... the people of Chicago, SAVE THE PATIENT, a not-for-profit patient-focused ... Health," on Chicago Access Network (CAN-TV) on Monday, December 8, ... , Monday,s program will feature ...
... Blue Cross and Blue Shield,in New Hampshire announced today ... over 220 not-for-profit organizations in 2009 as part of,the ... and Blue,Shield Foundation will match 50 percent of associate ... , "Our associates ...
... (NYSE: CMN ) will hold a conference call ... October 31, 2008 on December 5, 2008 at 11:00 AM ... Diker, Chairman; Andrew A. Krakauer, President; Craig A. Sheldon, Senior ... Minntech Corporation. Minntech is a Cantel subsidiary. The first quarter ...
... has announced the launch of a new health website providing in-depth ... With new advances in medicine, more and more patients are finding ... cancer. , , Responding ... risk factors, screening procedures and drugs to treat it, EIN News ...
... and screening have contributed greatly to the 13 percent decline ... a supporting role, according to new research from David Cutler ... to report a long-term decline in cancer mortality, Cutler,s is ... Published in the fall edition of the Journal of ...
... Processing and Payment Challenges for Healthcare Providers , ... Inc. (NYSE: STI ) today announced a new ... sizes, as well as hospitals. SunTrust eClaim Revenue Gateway helps ... and processing so that they can focus more time and ...
Cached Medicine News:Health News:The Gift of Health Caring at End of Life 2Health News:Anthem Blue Cross and Blue Shield in New Hampshire Associates Pledge More Than $260,000 to Community Organizations 2Health News:Anthem Blue Cross and Blue Shield in New Hampshire Associates Pledge More Than $260,000 to Community Organizations 3Health News:Cantel Medical Corp. to Hold Conference Call to Discuss Results for Its First Quarter Ended October 31, 2008 2Health News:EIN News Introduces 'Breast Cancer News Today'; Website Offers Information on Risk Factors, Treatment, Drugs 2Health News:Drop in cancer deaths tied primarily to gains in behavior and screening 2Health News:Healthcare Providers Now Able to Perform Real-Time Patient Eligibility Verification 2Health News:Healthcare Providers Now Able to Perform Real-Time Patient Eligibility Verification 3Health News:Healthcare Providers Now Able to Perform Real-Time Patient Eligibility Verification 4
Bipolar forceps...
... Nucleic Acid Hybridization Assay with ... for the Qualitative Detection of ... and 68 and Analysis of ... in Cervical Specimens: HPV Types ...
... radiation protection-0.62mm (+/- .05)Pb lead glass equivelant ... their level of protection, they are incredibly ... on your bridge while hugging your face ... corrective lenses, you can order Leaded Eyeglasses ...
... in the world, there is a now a ... VVC in female patients. CanDia5® is a simple-to-use, ... Candida antigens almost instantaneously (within 5 minutes) with ... is no similar POC product for VVC diagnosis ...
Medicine Products: